ArticleFrontiers in oncology2025
The value of
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to investigate the relationship between metabolic parameters based on Methods: In this single-center retrospective study, 115 patients with advanced NSCLC who underwent PD-1/PD-L1 ICI with/without chemotherapy with baseline Results: A total of 115 patients were enrolled in the group. After univariate and multivariate analyses, MTVwb [P = 0.002, HR 3.906 (3.644 - 9.279)] and treatment modality [P < 0.001, HR 8.11 (2.51 - 26.21)] were identified as independent prognostic factors for DCB. MTVwb [P = 0.012, HR 2.041 (1.173-3.552)] and treatment modality [P = 0.030, HR 2.045 (1.073 - 3.896)] are independent prognostic factors for PFS, while MTVwb [P =0.013, HR 4.173 (1.356-12.842)] is an independent influencing factor for OS. In the immunotherapy combination group, there was a significant correlation between PD-L1 expression and TLGwb (p Conclusions: Among patients with advanced NSCLC who received PD-1/PD-L1 ICIs in combination or without chemotherapy, MTVwb was an independent influencing factor for DCB, PFS, and OS. The treatment modality is also an independent influencing factor for DCB and PFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.